Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFFECT I: Epanova for Liver Fat
NCT02354976Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eicosapentaenoic acid + docosahexaenoic acid in non-alcoholic fatty liver disease (NAFLD), sponsored by AstraZeneca. Started Sep 2015; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02354976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354976.